In January, Aurora Cannabis announced a C$1.1bn purchase of CanniMed Therapeutics. After a more than fourfold increase in its share price over the year, its enterprise value is an eye-watering 164 times last year’s revenues. Another puffed-up share is Canopy Growth, trading at three times its price … Read More
The post Don’t get too high on cannabis stocks such as Aurora, Canopy Growth and Cronos appeared first on Dagga Magazine.